Remicade and Hepatobiliary disease - a phase IV clinical study of FDA data

Summary:

Hepatobiliary disease is reported as a side effect among people who take Remicade (infliximab), especially for people who are male, 20-29 old, also take Hydrocortisone, and have Ankylosing spondylitis.

The phase IV clinical study analyzes which people have Hepatobiliary disease when taking Remicade. It is created by eHealthMe based on reports of 222,651 people who have side effects when taking Remicade from the FDA, and is updated regularly.

What is Remicade?

Remicade has active ingredients of infliximab. It is often used in crohn's disease. eHealthMe is studying from 224,011 Remicade users. Check the latest studies of Remicade.

What is Hepatobiliary disease?

Hepatobiliary disease (diseases affect the liver and/or biliary tract) is found to be associated with 91 drugs and 245 conditions by eHealthMe. Check the latest studies of Hepatobiliary disease.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 27, 2026

222,651 people reported to have side effects when taking Remicade.
Among them, 15 people (0.01%) have Hepatobiliary disease.

Could Remicade cause Hepatobiliary disease?

Among these 15 people:

What is the gender of people who have Hepatobiliary disease when taking Remicade? *

female: 50 %
male: 50 %

What is the age of people who have Hepatobiliary disease when taking Remicade? *

What are other drugs people take besides Remicade? *

What are other side effects people have besides Hepatobiliary disease? *

Gastrointestinal Disorder (functional problems of gastrointestinal tract): 6 people, 40.00%
Skin Disorder (skin disease): 6 people, 40.00%
Respiratory Disorder (respiratory disease): 5 people, 33.33%
Nervous System Disorder (a general class of medical conditions affecting the nervous system): 5 people, 33.33%
Mediastinal Disorder (disease of mediastinum): 5 people, 33.33%
Adverse Event: 5 people, 33.33%
Cardiac Disorder: 5 people, 33.33%
Pneumonia: 4 people, 26.67%
Infection: 4 people, 26.67%
Infestation (the state of being invaded or overrun by parasites): 4 people, 26.67%

What are the existing conditions these people have? *

Metastatic Malignant Melanoma (spreadable cancer tumour of melanine): 3 people, 20.00%
Ankylosing Spondylitis (type of arthritis affecting the spine): 3 people, 20.00%
Pustular Psoriasis (raised bumps on the skin that are filled with pus): 1 person, 6.67%
Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 1 person, 6.67%
Psoriasis (immune-mediated disease that affects the skin): 1 person, 6.67%
Malignant Melanoma Stage Iv (the cancer has spread to other places in the body, such as the lung, liver, brain, bone, soft tissue, or gastrointestinal (gi) tract. cancer may have spread to places in the skin far away from where it first started): 1 person, 6.67%
Malignant Melanoma Stage Iii (cancer has spread to one or more lymph nodes): 1 person, 6.67%
Erythrodermic Psoriasis (generalized redness of the skin): 1 person, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Remicade and have Hepatobiliary disease?

- Check whether Hepatobiliary disease is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Remicade:

Remicade (224,011 reports)

Browse all side effects of Remicade:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hepatobiliary disease:

Hepatobiliary disease (91 drugs)

Browse all the conditions that are associated with Hepatobiliary disease:

Hepatobiliary disease (245 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on infliximab (the active ingredients of Remicade) and Remicade (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.